Search

Your search keyword '"Endari (Medication)"' showing total 276 results
Start Over Descriptor "Endari (Medication)"
276 results on '"Endari (Medication)"'

1. ANI Pharmaceuticals announces FDA approval, launch of L-Glutamine oral powder

Subjects
United States. Food and Drug Administration, Generic drugs, Glutamine, Drug approval, Business, News, opinion and commentary, Endari (Medication)
Abstract

ANI Pharmaceuticals announced that following final approval from the U.S. Food and Drug Administration, FDA, for its Abbreviated New Drug Application, ANDA, the Company launched L-Glutamine Oral Powder. ANI's L-Glutamine [...]

Published
2024

2. Emmaus Life Sciences Reports Quarterly Financial Results

Subjects
Sickle cell anemia -- Care and treatment, Company earnings/profit, Business, News, opinion and commentary, Endari (Medication)
Abstract

TORRANCE, Calif., Sept. 10, 2024 /PRNewswire/ --Emmaus Life Sciences, Inc. (OTC Markets: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its [...]

Published
2024

3. Emmaus Life Sciences' Endari gets marketing authorization from Puerto Rico

Subjects
Sickle cell anemia, Glutamine, Marketing, Pharmaceuticals and cosmetics industries, Endari (Medication)
Abstract

Emmaus Life Sciences, Inc., a leader in sickle cell disease (SCD) treatment, announced that it has received marketing authorization from the Puerto Rico Department of Health for Endari (L-glutamine oral [...]

Published
2024

4. Cybersecurity Industry Veteran Nils Puhlmann Launches Endari to Help SMBs and Startups Build Holistic Cybersecurity Programs and Achieve Cybersecurity Independence

Subjects
Internet -- Safety and security measures, Cyberterrorism, New business enterprises, Internet security, General interest, News, opinion and commentary, Endari (Medication)
Abstract

SAN FRANCISCO: ENDARI has issued the following news release: Endari, a pioneering cybersecurity company, has announced its official launch from stealth mode by Nils Puhlmann, a seasoned cybersecurity veteran with [...]

Published
2024

5. Cybersecurity Industry Veteran Nils Puhlmann Launches Endari to Help SMBs and Startups Build Holistic Cybersecurity Programs and Achieve Cybersecurity Independence

Subjects
Internet -- Safety and security measures, Cyberterrorism -- Surveys, New business enterprises -- Surveys, Internet security, Business, Business, international, Endari (Medication)
Abstract

New Survey Highlights Over-Confidence Across SMBs and Startups Who Admit They Have No Security Plan and Experienced Cyber Breaches SAN FRANCISCO -- Endari,a pioneering cybersecurity company, has today announced its [...]

Published
2024

6. Emmaus Life Sciences Reports 2023 Financial Results

Subjects
Sickle cell anemia, Company earnings/profit, Business, Endari (Medication)
Abstract

TORRANCE, Calif: Emmaus Life Sciences, Inc. (OTCPK: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of [...]

Published
2024

7. ANI Pharmaceuticals Reports the FDA Approval and Launch of L-Glutamine Oral Powder

Subjects
United States. Food and Drug Administration, ANI Pharmaceuticals Inc., Generic drugs, Glutamine, Drug approval, Pharmaceutical industry, General interest, News, opinion and commentary, Endari (Medication)
Abstract

PRINCETON: ANI Pharmaceuticals, Inc. announced that following final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application, the Company launched L-Glutamine Oral Powder. ANI's L-Glutamine [...]

Published
2024

8. ANI Pharmaceuticals Announces the FDA Approval and Launch of L-Glutamine Oral Powder

Subjects
United States. Food and Drug Administration -- International economic relations, ANI Pharmaceuticals Inc. -- International economic relations, Generic drugs, Glutamine, Drug approval, Pharmaceutical industry -- International economic relations, Banking, finance and accounting industries, Business, Endari (Medication)
Abstract

PRINCETON, N.J., July 15, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that following final approval from the U.S. Food and Drug Administration [...]

Published
2024

10. Emmaus Life Sciences Announces Outcome of FDA Inspection of Postmarketing Adverse Drug Experience Compliance Program

Subjects
United States. Food and Drug Administration, Sickle cell anemia -- Drug therapy, Regulatory compliance, Business, News, opinion and commentary, Endari (Medication)
Abstract

TORRANCE, Calif., July 12, 2024 /PRNewswire/ --Emmaus Life Sciences, Inc. (OTCPK: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced receiving the coveted [...]

Published
2024

11. Emmaus Life Sciences Reports 2023 Financial Results

Subjects
Endari (Medication)
Abstract

ENPNewswire-July 4, 2024--Emmaus Life Sciences Reports 2023 Financial Results (C)2024 ENPublishing - http://www.enpublishing.co.uk Release date- 03072024 - TORRANCE - Emmaus Life Sciences, Inc. (OTCPK: EMMA), a commercial-stage biopharmaceutical company and [...]

Published
2024

12. Emmaus Life Sciences Reports 2023 Financial Results

Subjects
Sickle cell anemia -- Care and treatment, Company earnings/profit, Business, News, opinion and commentary, Endari (Medication)
Abstract

TORRANCE, Calif., July 3, 2024 /PRNewswire/ --Emmaus Life Sciences, Inc. (OTCPK: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial [...]

Published
2024

13. Literature Review & Commentary

Author

Gaby, Alan R.

Subjects
Infection control, Ivermectin, Health, Endari (Medication)
Abstract

Is Ivermectin an Effective Treatment for COVID-19? The authors reviewed 24 randomized controlled trials involving 3,406 participants that examined the effect of ivermectin in people with, or at high risk [...]

Published
2021

14. Emmaus Life Sciences Receives Marketing Authorization for Puerto Rico

Subjects
Sickle cell anemia, Glutamine, Marketing, General interest, News, opinion and commentary, Endari (Medication)
Abstract

TORRANCE, Calif: Emmaus Life Sciences, Inc. has issued the following news release: Emmaus Life Sciences, Inc. (OTCQX: EMMA), a leader in sickle cell disease (SCD) treatment, today announced that it [...]

Published
2024

15. Emmaus Life Sciences Receives Marketing Authorization for Puerto Rico

Subjects
Sickle cell anemia, Glutamine, Marketing, General interest, News, opinion and commentary, Endari (Medication)
Abstract

TORRANCE, Calif., Feb. 2, 2024 /PRNewswire-HISPANIC PR WIRE/ --Emmaus Life Sciences, Inc. (OTCQX: EMMA), a leader in sickle cell disease (SCD) treatment, today announced that it has received marketing authorization [...]

Published
2024

16. Emmaus Life Sciences Receives Marketing Authorization for Puerto Rico

Subjects
Sickle cell anemia, Glutamine, Marketing, Business, News, opinion and commentary, Endari (Medication)
Abstract

TORRANCE, Calif., Feb. 2, 2024 /PRNewswire/ --Emmaus Life Sciences, Inc. (OTCQX: EMMA), a leader in sickle cell disease (SCD) treatment, today announced that it has received marketing authorization from the [...]

Published
2024

17. Understanding Sickle Cell Disease: Epidemiology, Treatment, and Market Outlook

Subjects
Pfizer Inc. -- Forecasts and trends, Vertex Pharmaceuticals Inc. -- Forecasts and trends, Novo Nordisk A/S -- Forecasts and trends, Sickle cell anemia -- Forecasts and trends, Gene mutations -- Forecasts and trends, Hemoglobin -- Forecasts and trends, Blood transfusion -- Forecasts and trends, Glutamine -- Forecasts and trends, Epidemiology -- Forecasts and trends, Disease susceptibility -- Forecasts and trends, Pharmaceutical industry -- Forecasts and trends, Market trend/market analysis, Business, News, opinion and commentary, Endari (Medication), Adakveo (Medication), Oxbryta (Medication)
Abstract

DUBLIN, Nov. 22, 2023 /PRNewswire/ -- The https://www.researchandmarkets.com/reports/5852749/us-sickle-cell-disease-market-insight?utm_source=CI&utm_medium=PressRelease&utm_code=xtk2gl&utm_campaign=1912752+-+Understanding+Sickle+Cell+Disease%3a+Epidemiology%2c+Treatment%2c+and+Market+Outlook&utm_exec=cari18prd report has been added toResearchAndMarkets.com's offering. Sickle cell disease (SCD) is a genetic blood disorder characterized by abnormal hemoglobin, leading to complications [...]

Published
2023

18. Emmaus Life Sciences Reports Q3 2023 Financial Results

Subjects
Sickle cell anemia, Company earnings/profit, General interest, News, opinion and commentary, Endari (Medication)
Abstract

TORRANCE, Calif: Emmaus Life Sciences, Inc. has issued the following news release: Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell [...]

Published
2023

19. Emmaus Life Sciences Reports Q3 2023 Financial Results

Subjects
Endari (Medication)
Abstract

ENPNewswire-November 15, 2023--Emmaus Life Sciences Reports Q3 2023 Financial Results (C)2023 ENPublishing - http://www.enpublishing.co.uk Release date- 14112023 - TORRANCE - Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company [...]

Published
2023

20. Emmaus Life Sciences Reports Q3 2023 Financial Results

Subjects
Sickle cell anemia -- Care and treatment, Company earnings/profit, Business, News, opinion and commentary, Endari (Medication)
Abstract

TORRANCE, Calif., Nov. 14, 2023 /PRNewswire/ --Emmaus Life Sciences, Inc.(OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition [...]

Published
2023

23. Emmaus Life Sciences Receives Marketing Authorization for Endari in Oman

Subjects
Sickle cell anemia, Glutamine, Marketing, Business, News, opinion and commentary, Endari (Medication)
Abstract

Sickle Cell Disease Treatment Commercially Available in Five GCC Countries TORRANCE, Calif., July 13, 2023 /PRNewswire/ --Emmaus Life Sciences, Inc.(OTCQX: EMMA), a leader in sickle cell disease treatment, today announced [...]

Published
2023

24. Emmaus Life Sciences Receives Endari(r) Marketing Authorization from the Bahrain NHRA

Subjects
Sickle cell anemia, Marketing, General interest, News, opinion and commentary, Endari (Medication)
Abstract

TORRANCE: Emmaus Life Sciences, Inc has issued the following news release: Emmaus Life Sciences, Inc. (OTCQX: EMMA), a leader in sickle cell disease treatment, announced today that it has received [...]

Published
2023

25. Emmaus Life Sciences Reports Management Changes

Subjects
Sickle cell anemia, Glutamine, Chairpersons, Health, Endari (Medication)
Abstract

2023 SEP 4 (NewsRx) -- By a News Reporter-Staff News Editor at Hematology Week -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment [...]

Published
2023

27. Emmaus Life Sciences Receives Endari Marketing Authorization from the Bahrain NHRA

Subjects
Sickle cell anemia, Marketing, Business, News, opinion and commentary, Endari (Medication)
Abstract

TORRANCE, Calif., May 31, 2023 /PRNewswire/ --Emmaus Life Sciences, Inc.(OTCQX: EMMA), a leader in sickle cell disease treatment, announced today that it has received a Medicine Registration Certificate (DRN-10164/23) from [...]

Published
2023

28. Emmaus Life Sciences Reports Q 1 2023 Financial Results and Provides Business Update

Subjects
Sickle cell anemia, Stock options, Company earnings/profit, Business, Endari (Medication)
Abstract

TORRANCE, Calif: Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of [...]

Published
2023

29. Emmaus Life Sciences Reports Q1 2023 Financial Results and Provides Business Update

Subjects
Sickle cell anemia, Stock options, Company earnings/profit, Business, News, opinion and commentary, Endari (Medication)
Abstract

TORRANCE, Calif., May 15, 2023 /PRNewswire/ --Emmaus Life Sciences, Inc.(OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition [...]

Published
2023

30. Emmaus Life Sciences Provides Interim Shipment Data

Subjects
Endari (Medication)
Abstract

ENPNewswire-April 4, 2023--Emmaus Life Sciences Provides Interim Shipment Data (C)2023 ENPublishing - http://www.enpublishing.co.uk Release date- 03042023 - TORRANCE - Emmaus Life Sciences, Inc. (OTCQX: EMMA), a leader in sickle ell [...]

Published
2023

31. Emmaus Life Sciences Reports 2022 Financial Results and Provides Business Update

Subjects
Sickle cell anemia, Company earnings/profit, Business, Endari (Medication)
Abstract

TORRANCE, Calif: Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported its results of operation for the year [...]

Published
2023

32. Emmaus Life Sciences Reports 2022 Financial Results and Provides Business Update

Subjects
Sickle cell anemia, Company earnings/profit, Business, News, opinion and commentary, Endari (Medication)
Abstract

TORRANCE, Calif., March 31, 2023 /PRNewswire/-- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported its results of [...]

Published
2023

33. Emmaus Life Sciences Receives Marketing Authorization for Endari® in Oman

Subjects
Sickle cell anemia, Glutamine, Marketing, Advertising, marketing and public relations, Endari (Medication)
Abstract

2023 JUL 29 (VerticalNews) -- By a News Reporter-Staff News Editor at Marketing Weekly News -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a leader in sickle cell disease treatment, announced [...]

Published
2023

34. Emmaus Life Sciences' Endari receives Oman Ministry of Health marketing authorisation

Subjects
Sickle cell anemia, Glutamine, Marketing, Chemistry, Endari (Medication)
Abstract

M2 PHARMA-July 14, 2023-Emmaus Life Sciences' Endari receives Oman Ministry of Health marketing authorisation (C)2023 M2 COMMUNICATIONS Emmaus Life Sciences, Inc. (OTCQX: EMMA), a California-based company that deals with sickle [...]

Published
2023

35. Emmaus Life Sciences' Endari receives Oman Ministry of Health marketing authorisation

Subjects
Sickle cell anemia, Glutamine, Marketing, Business, Endari (Medication)
Abstract

M2 EQUITYBITES-July 14, 2023-Emmaus Life Sciences' Endari receives Oman Ministry of Health marketing authorisation (C)2023 M2 COMMUNICATIONS http://www.m2.co.uk Emmaus Life Sciences, Inc. (OTCQX: EMMA), a California-based company that deals with [...]

Published
2023

36. Emmaus Life Sciences submits MAA to Swissmedic for Endari

Subjects
Sickle cell anemia, Orphan drugs, Drug approval, Business, News, opinion and commentary, Endari (Medication)
Abstract

Emmaus Life Sciences announced that it has received confirmation from the Swiss Agency for Therapeutic Products of Emmaus' application for Marketing Authorization for Endari in Switzerland. Swissmedic is responsible for [...]

Published
2021

37. Dr. Niihara Meets with Local Indian Governor

Subjects
Sickle cell anemia, Governors, General interest, News, opinion and commentary, Endari (Medication)
Abstract

TORRANCE: Emmaus Life Sciences, Inc has issued the following news release: Emmaus Life Sciences, Inc. (OTCQX: EMMA), announced today that Dr. Yutaka Niihara, Chairman and Chief Executive Officer of the [...]

Published
2022

38. Dr. Niihara Feted by Indian Government in Recognition of the Development of Endari(r)

Subjects
Sickle cell anemia, Skyscrapers, International trade, Tall buildings, International trade, General interest, News, opinion and commentary, Endari (Medication)
Abstract

TORRANCE: Emmaus Life Sciences, Inc. has issued the following news release: Emmaus Life Sciences, Inc. (OTCQX: EMMA), announced today that Dr. Yutaka Niihara, Chairman and Chief Executive Officer of the [...]

Published
2022

39. Dr. Niihara Meets with Local Indian Governor

Subjects
Sickle cell anemia, Governors, Business, News, opinion and commentary, Endari (Medication)
Abstract

Cites Large, Unserved Needs of Sickle Cell Disease Patients TORRANCE, Calif., Dec. 20, 2022 /PRNewswire/ --Emmaus Life Sciences, Inc. (OTCQX: EMMA), announced today that Dr. Yutaka Niihara, Chairman and Chief [...]

Published
2022

40. Dr. Niihara Feted by Indian Government in Recognition of the Development of Endari

Subjects
Sickle cell anemia, Skyscrapers, International trade, Cabinet officers, Tall buildings, International trade, Business, News, opinion and commentary, Endari (Medication)
Abstract

Celebrity Event Hosted in Mumbai, India TORRANCE, Calif., Dec. 19, 2022 /PRNewswire/ --Emmaus Life Sciences, Inc.(OTCQX: EMMA), announced today that Dr. Yutaka Niihara, Chairman and Chief Executive Officer of the [...]

Published
2022

41. Endari(r) Receives Kuwaiti Marketing Authorization

Subjects
Sickle cell anemia, Drug approval, Food supply, Marketing, General interest, News, opinion and commentary, Cooperation Council for the Arab States of the Gulf, Endari (Medication)
Abstract

TORRANCE Calif.: Emmaus Life Sciences, Inc. has issued the following news release: Emmaus Life Sciences, Inc. (OTCQX: EMMA), a leader in sickle cell disease treatment, announced today that it has [...]

Published
2022

42. Emmaus Life Sciences, Inc. - Endari Receives Kuwaiti Marketing Authorization

Subjects
Cooperation Council for the Arab States of the Gulf, Endari (Medication)
Abstract

ENPNewswire-December 8, 2022--Emmaus Life Sciences, Inc. - Endari Receives Kuwaiti Marketing Authorization (C)2022 ENPublishing - http://www.enpublishing.co.uk Release date- 07122022 - Emmaus Life Sciences, Inc. (OTCQX: EMMA), a leader in sickle [...]

Published
2022

43. Endari Receives Kuwaiti Marketing Authorization

Subjects
Sickle cell anemia, Drug approval, Food supply, Marketing, Business, News, opinion and commentary, Cooperation Council for the Arab States of the Gulf, Endari (Medication)
Abstract

Kuwait is Third Gulf Cooperation Council Country to Approve Endari TORRANCE Calif., Dec. 7, 2022 /PRNewswire/ --Emmaus Life Sciences, Inc.(OTCQX: EMMA), a leader in sickle cell disease treatment, announced today [...]

Published
2022

44. Emmaus Life Sciences submits MA application for Endari in Saudi Arabia

Subjects
Sickle cell anemia, Glutamine, Drug approval, Business, News, opinion and commentary, Endari (Medication)
Abstract

Emmaus Life Sciences announced that its application for Marketing Authorization for Endari in the Kingdom of Saudi Arabia has been accepted by the Saudi Food and Drug Authority. The SFDA's [...]

Published
2021

45. Emmaus Life Sciences Inc Annual Shareholders Meeting - Final

Subjects
Chairpersons, Insurance industry -- Officials and employees, Stockholders, Insurance industry, Business, Endari (Medication)
Abstract

Presentation YUTAKA NIIHARA, CHAIRMAN & CEO, EMMAUS LIFE SCIENCES, INC.: Good afternoon, ladies and gentlemen, and welcome to the 2021 Annual Stockholders Meeting of Emmaus Life Sciences. I am Yutaka [...]

Published
2021

49. Emmaus Life Sciences Reports Q3 2022 Financial Results and Provides Business Update

Subjects
Sickle cell anemia, Company earnings/profit, Business, News, opinion and commentary, Endari (Medication)
Abstract

TORRANCE, Calif., Nov. 14, 2022 /PRNewswire/ --Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its results [...]

Published
2022

50. C O R R E C T I O N -- Emmaus Life Sciences, Inc

Subjects
PR Newswire Association L.L.C., Sickle cell anemia -- Care and treatment, News agencies, Insurance industry, Insurance industry, Business, News, opinion and commentary, Endari (Medication)
Abstract

In the news release, Emmaus Life Sciences Reports Q3 2022 Financial Results and Provides Business Update, issued 14-Nov-2022 by Emmaus Life Sciences, Inc. over PR Newswire, we are advised by [...]

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results